Prostaglandina

Alprostadil CAS 745-65-3

Obter um orçamento

Última mensagem

Exposto: Os únicos 5 fabricantes chineses de retatrutida que efetivamente enviam para os EUA

2025-12-04

Tesofensina CAS 195875-84-4 | Ingrediente farmacêutico ativo e intermediário | Ningbo Kilo Biotechnology Co., Ltd.

Encomendar Tesofensine a granel sem mínimos: 3 fornecedores que quebram as regras de MOQ!

2025-11-17

Choques de preços da Tesofensina a granel: O que 12 laboratórios realmente pagam (Exposto!)

2025-11-17

Tabela de doses de retatrutida surpreendentemente simples para uma perda de peso de 17% em 6 meses!

2025-11-17

Compreender a dosagem de retatrutida: O que a investigação científica revela sobre o controlo de peso

2025-11-17

Hacks de seguros: Reduzir os custos do Retatrutide em 80% com ESTA estratégia de dosagem

2025-11-17

Alprostadil CAS 745-65-3

Alprostadil
745-65-3

Prostaglandina e intermediário

Embalagem de 1kg/saco a 25kg/tambor conforme o pedido.

Modificação de moléculas a pedido (escala de gramas a quilos).

Nome do produto

Alprostadil

N.º CAS.

745-65-3

Pureza

NLT 99.0%

Embalagem

Embalagem de 1kg/saco a 25kg/tambor conforme o pedido.

Fórmula molecular

C20H34O5

Peso molecular

354.5

SORRISOS

CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O

Nome IUPAC

7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid

Sinónimo

alprostadil; Prostaglandin E1; 745-65-3; PGE1; Edex; Caverject; Muse; Befar; Alprostadilum; Vitaros; Prink; Prostin VR Pediatric; PGE-1; Prostavasin; Caverject Impulse; PGE1alpha; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; DTXSID9022578; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; U-10136; CHEBI:15544; ONO-1608; 9-oxo-11R,15S-dihydroxy-13E-prostaenoic acid; F5TD010360; NSC-165559; U-10,136; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; DTXCID502578; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-; Prostine VR; Lipo PGE1; Lipo-PGE1; Prostaglandin E1alpha; Viridal duo; NSC165559; 7-((1R,2R,3R)-3-hydroxy-2-((E,3S)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid; Viridal 5; 7-((1R,2R,3R)-3-Hydroxy-2-((1E,3S)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid; Viridal 10; Viridal 20; RefChem:56455; C01EA01; G04BE01; Muse (intraurethral alprostadil suppository); 212-017-2; Prostin; Prostin VR; Topiglan; Femprox; Alprox-TD; l-Prostaglandin E1; Liprostin; Prostandin; 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid; MFCD00077860; Alprostadil(Caverject); (-)-Prostaglandin E1; CHEMBL495; Vasaprostan; Minprog; Sugiran; Viridal; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Lipoprost; Promostan; Prostivas; Alista; FemLife; l-PGE1; RayVa; (1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid; 7-[(1r,3r)-3-Hydroxy-2-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-5-Oxocyclopentyl]heptanoic Acid; Caverject (TN); SMR000112594; Befar (TN); Prink (TN); Edex (TN); Muse (TN); (-)-Protaglandin E1; U 10136; SR-01000597593; MR-256; Alprostadilum [INN-Latin]; Prostin VR pediatric (TN); Alprostadil Prostoglandin E1; BML1-F06; UNII-F5TD010360; Alprostadil(usan); (1R,2R,3R)-3-Hydroxy-2-[(E)-(3S)-3-hydroxy-1-octenyl]-5-oxocyclopentaneheptanoic acid; HEI-507; NCGC00016535-01; Alprostadil; 7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; CAS-745-65-3; ONO 1608; XPG; EINECS 212-017-2; (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate; NSC 165559; Alprostadil [USAN:USP:INN:BAN:JAN]; 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid; PGE1;Prostaglandin E1; AI3-62116; Prestwick2_001018; Prestwick3_001018; ALPROSTADIL [INN]; ALPROSTADIL [JAN]; ALPROSTADIL [USAN]; ALPROSTADIL [VANDF]; PGE1 (Prostaglandin E1); ALPROSTADIL [MART.]; SCHEMBL33317; ALPROSTADIL [USP-RS]; ALPROSTADIL [WHO-DD]; BSPBio_001175; BSPBio_001488; MLS000758964; MLS001424250; BIDD:GT0747; PROSTAGLANDIN E1 [MI]; BPBio1_001293; GTPL1882; orb1307980; Alprostadil (JP17/USP/INN); ALPROSTADIL [ORANGE BOOK]; PGE1, Prostaglandin E1, powder; ALPROSTADIL [USP IMPURITY]; GLXC-20048; HMS1361K10; HMS1571K17; HMS1791K10; HMS1989K10; HMS2052L11; HMS2090L08; HMS2098K17; HMS3268I09; HMS3402K10; HMS3414N09; HMS3648O17; HMS3678N07; HMS3715K17; ALPROSTADIL [USP MONOGRAPH]; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; BCP01740; EX-A1411; HY-B0131; MSK10682; Tox21_110482; 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid; BDBM50101853; l-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid; LMFA03010134; s1508; AKOS015961103; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-; AC-6095; BCP9000277; CCG-101188; CS-1905; DB00770; FA31828; NC00438; IDI1_033958; SMP2_000271; NCGC00016535-19; NCGC00025234-02; NCGC00025234-03; NCGC00025234-04; NCGC00025234-05; AS-16360; Prostaglandin E1, PGE1, 745-65-3; Alprostadil 100 microg/mL in Acetonitrile; 11,15-Dihydroxy-9-oxoprost-13-en-1-oate; AB00514004; NS00009541; P1917; ST50826271; Alprostadil, meets USP testing specifications; C04741; C76381; D00180; Prostaglandin E1, >=98% (HPLC), synthetic; AB00514004-06; AB00514004-08; AB00514004_09; 745P653; EN300-22411483; Q579348; SR-01000946253; SR-01000597593-1; SR-01000597593-5; SR-01000597593-6; SR-01000946253-1; BRD-K52459643-001-06-0; BRD-K52459643-001-10-2; BRD-K52459643-001-15-1; BRD-K52459643-001-17-7; (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate; (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid; Alprostadil, European Pharmacopoeia (EP) Reference Standard; (13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid; (11|A,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid; (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid; 11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (ACD/Name 4.0); 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate; 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid; Alprostadil, United States Pharmacopeia (USP) Reference Standard; (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate; (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid; (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate; (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid; (11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l-; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11a,13E,15S)-; Prostaglandin E1, synthetic, powder, BioReagent, suitable for cell culture; 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]heptanoic acid; Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-; Prostaglandin E1, powder, gamma-irradiated, BioXtra, suitable for cell culture; 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]hepta noic acid; Prostaglandin E1;(11a,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid;Prostandin;3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclop entaneheptanoic acid; ProstaglandinE1; Prostaglandine E; PGE1 Oligomer; Lipo-alprostadil; Prostaglandin K1; AC1NQXHQ; GMVPRGQOIOIIMI-DWKJAMRDSA-N; D0I4DQ; D0N2EF; Alprostadil (JP15/USP/INN); C20H34O5; SYN3025; MR 256; Alprostadil [USAN:BAN:INN:JAN]; Alprostadil [USAN:INN:BAN:JAN]; AMY30076; ZINC3813088; (C20-H34-O5)x-; ACN-036193; C20-H34-O5; CID5280723; RP17688; CID:5280723; BC205461; CPD000112594; K274; SAM001246840; SAM001246845; SAM001247093; SID:53790811; AB0014134; AB2000131; B2154; A11820; Prostaglandin E1;Edex;Muse;Liprostin;Caverject; A838163; D000527; B0084-299024; (11?,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid; (11a,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid; (11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid; Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, ()-; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11?,13E,15S)-; Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (Z)-7-[(1r,2r,3r)-3-Hydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]-5-Oxo-Cyclopentyl]hept-5-Enoic Acid; 119314-69-1; P2E